Foxp3+ CD25+ CD4+ Natural Regulatory T Cells in Dominant Self-tolerance and Autoimmune Disease
Overview
General Surgery
Authors
Affiliations
Naturally arising CD25+ CD4+ regulatory T (Treg) cells, most of which are produced by the normal thymus as a functionally mature T-cell subpopulation, play key roles in the maintenance of immunologic self-tolerance and negative control of a variety of physiological and pathological immune responses. Natural Tregs specifically express Foxp3, a transcription factor that plays a critical role in their development and function. Complete depletion of Foxp3-expressing natural Tregs, whether they are CD25+ or CD25-, activates even weak or rare self-reactive T-cell clones, inducing severe and widespread autoimmune/inflammatory diseases. Natural Tregs are highly dependent on exogenously provided interleukin (IL)-2 for their survival in the periphery. In addition to Foxp3 and IL-2/IL-2 receptor, deficiency or functional alteration of other molecules, expressed by T cells or non-T cells, may affect the development/function of Tregs or self-reactive T cells, or both, and consequently tip the peripheral balance between the two populations toward autoimmunity. Elucidation of the molecular and cellular basis of this Treg-mediated active maintenance of self-tolerance will facilitate both our understanding of the pathogenetic mechanism of autoimmune disease and the development of novel methods of autoimmune disease prevention and treatment via enhancing and re-establishing Treg-mediated dominant control over self-reactive T cells.
Occupational dust and chemical exposures and the development of autoimmune rheumatic diseases.
Nikpour M, Morrisroe K, Calderone A, Yates D, Silman A Nat Rev Rheumatol. 2025; 21(3):137-156.
PMID: 39910253 DOI: 10.1038/s41584-024-01216-3.
Huang X, Zeng Y, Lin J, Liu H, Liang C, Chen Y Front Immunol. 2025; 15():1529226.
PMID: 39850891 PMC: 11754228. DOI: 10.3389/fimmu.2024.1529226.
Inhibition of skin fibrosis via regulation of Th17/Treg imbalance in systemic sclerosis.
Sekiguchi A, Shimokawa C, Kato T, Uchiyama A, Yokoyama Y, Ogino S Sci Rep. 2025; 15(1):1423.
PMID: 39789188 PMC: 11717915. DOI: 10.1038/s41598-025-85895-2.
MiR-27a inhibits the growth and metastasis of multiple myeloma through regulating Th17/Treg balance.
Lu W, Huang H, Xu Z, Xu S, Zhao K, Xiao M PLoS One. 2024; 19(10):e0311419.
PMID: 39413115 PMC: 11482689. DOI: 10.1371/journal.pone.0311419.
Hu J, Toyozumi T, Murakami K, Endo S, Matsumoto Y, Otsuka R Cancer Med. 2024; 13(17):e70179.
PMID: 39264227 PMC: 11391568. DOI: 10.1002/cam4.70179.